The results of the experiments on mice showed that the combination of immunotherapy with low-dose aspirin significantly increases the effectiveness of treatment of various forms of cancer.
Evidence of benefit of aspirin in the treatment of cancer has received scientists from the Institute of Francis Crick.
In the study of molecular mechanisms of growth and spread of malignant tumors of skin, colon and breast the attention of researchers was attracted to the idea of increased production in the body, particular molecules of prostaglandin E2 (PGE2), accompanying the emergence and proliferation of cancer cells.
A large concentration of PGE2 dramatically reduced the proper response of the immune system on cancer development. Scientists have suggested that the silencing of prostaglandin may positively affect the efficiency of the cancer treatment methods of immunotherapy. For this purpose, suitable specific inhibitors of COX, which include acetylsalicylic acid or aspirin.
Scientists have conducted a series of experiments on laboratory mice, which have previously triggered the development of cancer of the bowel, breast or skin. In the course of this research work, the researchers treated experimental animals with immunotherapy combined with low doses of aspirin. This strategy proved very effective and resulted in significant growth restriction of cancer cells and their destruction by the immune system of mice.
The authors of this discovery, we intend to continue the study of possibilities of combinations of aspirin with drugs immunotherapy to enhance the efficiency of treatment of oncological diseases of the skin, breast and stomach in animal models and go in a short time to test new anti-cancer technology in a clinical setting.